Cryo-Cell International Return on Equity

Cryo-Cell International (CCEL) currently reports a ROE of 17.19%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Cryo-Cell International's ROE history and peer comparisons.

Cryo-Cell International's ROE of 17.19% is higher than the Healthcare sector average of 11.15%. That is roughly 54.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cryo-Cell International's current 17.19% should be judged against Healthcare norms (sector average: 11.15%) and against CCEL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 17.19%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Cryo-Cell International, and consider following CCEL for alerts when major investors trade the stock.

Cryo-Cell International is classified in the Healthcare sector. On ROE, it currently shows 17.19% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CCEL with unrelated industries.